Plasma cells: a feasible therapeutic target in pulmonary fibrosis?
Eur Respir J
.
2022 Nov 24;60(5):2201748.
doi: 10.1183/13993003.01748-2022.
Print 2022 Nov.
Authors
Amanda T Goodwin
1
,
Paul W Noble
2
,
Amanda L Tatler
3
Affiliations
1
Centre for Respiratory Research, School of Medicine, Biodiscovery Institute, University of Nottingham, Nottingham, UK.
2
Department of Medicine, Women's Guild Lung Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
3
Centre for Respiratory Research, School of Medicine, Biodiscovery Institute, University of Nottingham, Nottingham, UK
[email protected]
.
PMID:
36423920
DOI:
10.1183/13993003.01748-2022
No abstract available
Publication types
Editorial
Comment
MeSH terms
Bleomycin
Fibroblasts / pathology
Humans
Plasma Cells
Pulmonary Fibrosis* / drug therapy
Pulmonary Fibrosis* / pathology
Substances
Bleomycin
Grants and funding
MR/P001327/1/MRC_/Medical Research Council/United Kingdom
MRF_MRF-091-0004-RG-TATLE/MRF/MRF/United Kingdom